Weight Loss Drug Will Be Offered for $499 a Month for Some PatientsNovo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?Novo Nordisk's Ozempic and Wegovy shortage is resolved, enhancing its market position and pricing power.
New Study Finds Wegovy Reduces COVID Death Risk By 33 PercentNovo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearingThe U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Ozempic and Wegovy linked to rare vision lossNovo Nordisk's drugs Ozempic and Wegovy linked to higher risk of vision loss.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
Weight Loss Drug Will Be Offered for $499 a Month for Some PatientsNovo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?Novo Nordisk's Ozempic and Wegovy shortage is resolved, enhancing its market position and pricing power.
New Study Finds Wegovy Reduces COVID Death Risk By 33 PercentNovo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearingThe U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Ozempic and Wegovy linked to rare vision lossNovo Nordisk's drugs Ozempic and Wegovy linked to higher risk of vision loss.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
What are the limits in the fight against obesity? Ozempic owner disappoints the marketNovo Nordisk faces challenges in sustaining growth with competition in obesity treatments, particularly after CagriSema's trial results.
Novo Nordisk Annual Sales Jump on Demand for Ozempic and WegovyNovo Nordisk reported strong earnings in 2024 but expects slower sales growth in 2025 due to competition.The company’s share price has fallen dramatically amid uncertainties in the obesity drug market.
What are the limits in the fight against obesity? Ozempic owner disappoints the marketNovo Nordisk faces challenges in sustaining growth with competition in obesity treatments, particularly after CagriSema's trial results.
Novo Nordisk Annual Sales Jump on Demand for Ozempic and WegovyNovo Nordisk reported strong earnings in 2024 but expects slower sales growth in 2025 due to competition.The company’s share price has fallen dramatically amid uncertainties in the obesity drug market.
Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: OzempicMehmet Oz's potential role in leading Medicare raises concerns due to his past connections with Novo Nordisk, makers of Ozempic.
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patientsOzempic is FDA approved to reduce risks associated with chronic kidney disease in diabetes patients.
Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?Denmark's economy heavily relies on Novo Nordisk and its diabetes medication Ozempic for growth and job creation.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Forget the shot. A weight loss pill saw promising results in Phase 1 testingAmycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.
Analysts say market forces will lower cost of obesity drugsCongressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.
Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: OzempicMehmet Oz's potential role in leading Medicare raises concerns due to his past connections with Novo Nordisk, makers of Ozempic.
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patientsOzempic is FDA approved to reduce risks associated with chronic kidney disease in diabetes patients.
Ozempic's biggest side effect: Turning Denmark into a 'pharmastate'?Denmark's economy heavily relies on Novo Nordisk and its diabetes medication Ozempic for growth and job creation.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Forget the shot. A weight loss pill saw promising results in Phase 1 testingAmycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.
Analysts say market forces will lower cost of obesity drugsCongressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptionsMany patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drugShares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptionsMany patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drugShares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.
Novo Nordisk's market value of $570 billion is more than Denmark's annual GDPDanish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.
Danish krone weakened by Novo Nordisk share price crashNovo Nordisk's disappointing drug trial results caused a significant drop in its share price, impacting Denmark's economy and currency.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.
Novo Nordisk's market value of $570 billion is more than Denmark's annual GDPDanish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.
Danish krone weakened by Novo Nordisk share price crashNovo Nordisk's disappointing drug trial results caused a significant drop in its share price, impacting Denmark's economy and currency.
I'm the Danish scientist who pioneered injectable drugs like Ozempic. Here are my 3 tips for inventing blockbuster products.Lotte Bjerre Knudsen's research was pivotal in transforming short-acting GLP-1 hormones into successful long-acting diabetes treatments like Ozempic.
Denmark gets Novo Nordisk to lower Ozempic pricesSanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimonyNovo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emergeThe introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profitsNovo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economyDenmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
Denmark gets Novo Nordisk to lower Ozempic pricesSanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimonyNovo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emergeThe introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profitsNovo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economyDenmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
Half of Denmark's GDP growth in 2024 will be thanks to Novo Nordisk, analysts predictNovo Nordisk is pivotal for Denmark's GDP growth in 2024, surpassing its Nordic peers.
Danish town where Ozempic is made has highest rates of overweight children in DenmarkNovo Nordisk's investment success is overshadowed by local socio-economic challenges in Kalundborg, including obesity and inadequate public services.
Half of Denmark's GDP growth in 2024 will be thanks to Novo Nordisk, analysts predictNovo Nordisk is pivotal for Denmark's GDP growth in 2024, surpassing its Nordic peers.
Danish town where Ozempic is made has highest rates of overweight children in DenmarkNovo Nordisk's investment success is overshadowed by local socio-economic challenges in Kalundborg, including obesity and inadequate public services.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Wegovy Approved to Cut Heart Disease and Stroke RiskWeight loss drugs approved for heart health benefitsSemaglutide linked to cardiovascular risk reduction
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Wegovy Approved to Cut Heart Disease and Stroke RiskWeight loss drugs approved for heart health benefitsSemaglutide linked to cardiovascular risk reduction
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEOThe U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side EffectsNovo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
The next big market for weight-loss drugs: childrenNovo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.
Sen. Bernie Sanders launches Senate investigation into 'high' pricing of Ozempic, WegovySen. Bernie Sanders investigating high drug prices for Ozempic and Wegovy.
Senate Committee Investigates Ozempic and Wegovy CostsThe Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer projectNovo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this yearNvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer projectNovo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this yearNvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
Ozempic and Wegovy could soon be challenged by China's generic competitorsIntensifying competition in Chinese market for Novo Nordisk's diabetes drug Ozempic and weight loss treatment Wegovy.